Tourette disorder treated with valproic acid

Clinical Neuropharmacology

Volumn 37, Issue 1, 2014, Pages 36-37

  Ye, Lu ^a   Lippmann, Steven ^b  

^a Methodist Medical Center of Illinois   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Attention deficit hyperactive disorder; Bipolar disorder; Tic disorder; Tourette's Disorder; Valproic acid

Indexed keywords

CHILD; ENZYME INHIBITORS; HUMANS; MALE; TOURETTE SYNDROME; VALPROIC ACID;

EID: 84895076923     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000013     Document Type: Article

References (7)

1. Centers for Disease Control and Prevention (CDC). Prevalence of diagnosed Tourette syndrome in persons aged 6-17 years-United States, 2007. MMWR Morb Mortal Wkly Rep 2009;58(21):581-585.
2. Saft C, Lauter T, Kraus PH, et al. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's disease patients: a case series. BMC Neurol 2006;6:11.
3. Peña J, Mora E, Cardozo J, et al. Comparison of the efficacy of carbamazepine, haloperidol and valproic acid in the treatment of children with Sydenham's chorea: clinical follow-up of 18 patients. Arq Neuropsiquiatr 2002;60(2-B):374-377. (Pubitemid 34728734)
4. Jankovic J, Jimenez-Shahed J, Brown LW. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010;81:70-73.
5. Singer HS. Treatment of tics and Tourette syndrome. Curr Treat Options Neurol 2010;12(6):539-561.
6. Lerner A, Bagic A, Simmons JM, et al. Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain 2012;135:1926-1936.
7. Allen KL, Waldvogel HJ, Glass M, et al. Cannabinoid (CB1), GABAA and GABAB receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat 2009;37(4):266-281.